quality assessment of blas, ndas, and andas (3of33) quality – oct. 16-17, 2019
Published 4 years ago • 646 plays • Length 25:06Download video MP4
Download video MP3
Similar videos
-
26:22
application manufacturing assessment (4of33) quality – oct. 16-17, 2019
-
19:09
the importance of quality in our medicines (2of33) quality – oct. 16-17, 2019
-
23:35
fda’s quality assessment and knowledge management - kasa (11of33) quality – oct. 16-17, 2019
-
24:48
fda perspectives on biosimilar bla-manufacturing (28of33) quality – oct. 16-17, 2019
-
16:35
application communications – quality assessment perspective
-
27:10
overview of post-approval chemistry, manufacture, and controls (cmc) changes to an nda - redi 2020
-
20:08
505(b)(2) nda or anda? (10of28) generic drugs forum – apr. 3-4, 2019
-
2:11:46
understanding how the public perceives and values pharmaceutical quality
-
2:35:24
an in-depth look at the final fda guidance: bioavailability studies submitted in ndas or inds
-
13:59
optimization of integrated quality assessment (iqa)
-
24:20
overview of the quality system regulation
-
23:39
building a better sterility assurance application
-
48:31
fda roundtable
-
20:14
generic drug product quality assessment (22of27) generic drugs forum 2018
-
1:10:48
cmc - nda requirements and common pitfalls of blas (14of15) redi – may 29-30, 2019
-
8:08
andas: pre-submission facility correspondence (pfc) related to prioritized generic drug submissions
-
17:27
opq integrated quality assessment (iqa) process (20/28) generic drugs forum 2017
-
3:07
what is usfda’s form 483?
-
18:34
alliance discussion with andi fristedt, fda